June 21, 2013

Oral Paricalcitol Reduces the Prevalence of Posttransplant Hyperparathyroidism: Results of an Open Label Randomized Trial


Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177

Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177

Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177
.   .   

Bone disease and secondary hyperparathyroidism are common following renal transplantation. This open-label randomized controlled trial compared the calcitriol analog paricalcitol to placebo, with a primary endpoint of hyperparathyroidism at one year post-transplant. There was less hyperparathyroidism in the paricalcitol-treated group. However, there was no difference in bone density between groups. Also, these patients were not compared to patients given active treatment with other agents, such s calcitriol.

Renal Transplantation

Tags: , , , , ,